SLU-PP-332

Status

No approved product. No FDA-approved labeling exists. Not an approved medicine in the United States, no approval elsewhere is listed in this site's sources; its status as a US dietary ingredient has not been verified for this entry, and it is an early-stage research chemical.

What it is

An early research molecule studied in mice for exercise-like metabolic signaling.

What published research measured

An agonist of the estrogen-related receptors, investigated as an exercise mimetic. Rodent work published from 2023 onward reported increased oxidative metabolism, improved endurance capacity and resistance to diet-induced obesity in treated mice. That is the whole of the evidence base. This entry does not cite any human study — no trials, pharmacokinetics or safety data — and the compound has not been through the preclinical toxicology that normally precedes a first human dose. The receptor family it targets is broadly expressed, including in cardiac tissue, so effects confined to skeletal muscle should not be assumed.

Source

Billon et al. 2023, ERR agonist exercise-mimetic rodent studies

Sources

• Primary source
• Research group publication record
• CDC handling principles